(CIX: WRAL30)  1,100.41  up arrow+1.23  (0.11 %)  Updated: 06:40 PM EDT, Aug 22 2014
(NQ: Apple)  101.32  up arrow+0.74  (0.74 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NY: QUINTILES)  55.74  down arrow-0.6  (-1.07 %)  Updated: 06:40 PM EDT, Aug 22 2014
(OP: BASF SE)  101.67  down arrow-1.03  (-1 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NQ: BioCryst)  12.82  up arrow+0.21  (1.67 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NQ: BioDelivery)  13.82  up arrow+0.36  (2.67 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NQ: CEMP)  9.45  up arrow+0.08  (0.85 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NQ: Cisco Systems)  24.65  down arrow-0.24  (-0.96 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NQ: Cree)  45.15  up arrow+0.08  (0.18 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NQ: DARA)  1.26  up arrow+0.01  (0.74 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NY: EMC CORPORATION)  29.64  up arrow+0.02  (0.07 %)  Updated: 06:40 PM EDT, Aug 22 2014
(NQ: Extreme Networks)  5.33  up arrow+0.1  (1.91 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NQ: FB)  74.57    (0 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NY: GLAXOSMITHKLINE)  47.68  down arrow-0.02  (-0.04 %)  Updated: 06:40 PM EDT, Aug 22 2014
(NQ: GOOG)  582.56  down arrow-0.81  (-0.14 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NY: IBM)  190.41  down arrow-0.82  (-0.43 %)  Updated: 06:40 PM EDT, Aug 22 2014
(NY: LH)  106.22  down arrow-0.6  (-0.56 %)  Updated: 06:40 PM EDT, Aug 22 2014
(OP: Lenovo Group)  30.48  down arrow-0.17  (-0.55 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NY: MRK)  59.17  up arrow+0.32  (0.54 %)  Updated: 06:40 PM EDT, Aug 22 2014
(NQ: Microsoft Corp)  45.15  down arrow-0.07  (-0.15 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NQ: NTAP)  41.00  up arrow+0.08  (0.2 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NY: NOVARTIS AG)  88.95    (0 %)  Updated: 06:40 PM EDT, Aug 22 2014
(OP: Novozymes A/S)  45.09  up arrow+0.22  (0.48 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NY: PFIZER)  28.92  up arrow+0.1  (0.35 %)  Updated: 06:40 PM EDT, Aug 22 2014
(NQ: Pozen)  7.77  up arrow+0.05  (0.58 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NY: RED HAT)  62.11  up arrow+0.54  (0.88 %)  Updated: 06:40 PM EDT, Aug 22 2014
(NQ: BBRY)  9.94  up arrow+0.1  (0.96 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NQ: Salix)  158.96  up arrow+0.66  (0.42 %)  Updated: 05:20 PM EDT, Aug 22 2014
(NQ: SQI)  15.40  up arrow+0.34  (2.26 %)  Updated: 05:20 PM EDT, Aug 22 2014

Posts tagged “Biotech & Life Science”

3:55 p.m. today

Doctor who survived Ebola: 'Please continue to pray for Liberia and the people of West Africa ...'

As one of few Ebola survivors with medical expertise, Dr. Kent Brantly seems keenly aware of the position his painful experience has put him in. He hasn't spoken yet about his plans, but spent much of his first public appearance pleading for help for countries still struggling with the virus.

Americans Ebola Americans Ebola

3:45 p.m. today

Premium Lock Exclusive: New Biotech Center CEO will 'push the envelope with new ideas and programs'

In the second part of an exclusive in-depth Q&A with Doug Edgeton, the new CEO of the North Carolina Biotechnology Center, the veteran life science executive talks about his goals, his background, and the Center's commitment to development of the sector across the state.

Douge Edgeton  Douge Edgeton

7:18 a.m. today

Premium Lock Exclusive: New Biotech Center CEO lays out future vision

Life science veteran executive Doug Edgeton, who once ran the Piedmont Research Park in Winston-Salem, spells out his vision for where he hopes to take the North Carolina Biotechnology Center as its new CEO in an exclusive Q&A with WRAL Tech Wire. He says N.C. has a fight on its hands to grow one of the nation's largest biotech industry clusters. But Edgeton believes he's ready for the job. Restoring state budget cuts is a "top priority" as well as recruiting and helping build new businesses. "We have to be creative in finding ways to bring technologies to the marketplace that will improve lives, create well-paying jobs and create wealth for the people of our state," Edgeton explains.

Doug Edgeton Doug Edgeton

1:06 p.m. yesterday

Premium Lock Clinverse CEO: Pharma industry changes mean more business opportunities

Denis Connaghan, Clinverse's chief executive officer, has $9.1 million in new funding to exploit changes in the pharmaceutical business that mean more opportunities for his clinical trials technology firm. He also talks about the challenges he has faced in his first year on the job in an exclusive Q&A for WRAL TechWire Insiders.

Clinverse Clinverse

10:01 a.m. yesterday

$15M Marcus Foundation grant boosts cord blood research at Duke

The Duke award enables cell therapy expert Joanne Kurtzberg, M.D., and leading autism authority Geraldine Dawson, Ph.D., professor of psychiatry and behavioral sciences, to pioneer new treatment approaches and cell-based therapies that could potentially benefit many autism patients.

Home Depot co-founder, philanthropist Bernie Marcus. Home Depot co-founder, philanthropist Bernie Marcus.

Updated 11:59 a.m. Wednesday

More than 60 startups join lineup for Tech Venture 2014

CED Tech Venture Conference The Council for Entrepreneurial development is going to swamp attendees at its annual venture conference with startup and emerging companies that just might be worth investment. The list of presenting companies grew to more than 60 with the list announced Wednesday.

Updated 10:12 a.m. Wednesday

Premium Lock Clinverse CEO: New venture funding to drive expansion, create new jobs

Denis Connaghan, Clinverse's chief executive officer for a year now, has wasted no time in putting his own stamp on the company. The clinical trials technology company has raised $9.1 million in new venture capital, landed a new high-profile investor, and will be gunning for more business as it aims for profitability in 2015. WRAL TechWire Insiders go inside the latest developments at Clinverse in an exclusive two-part Q&A.

Denis Connaghan Denis Connaghan

Updated 9:33 a.m. Wednesday

Some 200 NC firms, including several Triangle tech ventures, crack new Inc. 5000

Some 200 companies from around North Carolina - including several tech ventures based around the Triangle - are among the latest Inc. 5000 list released early Wednesday. We've got the list: Two Toasters, Netsertive, Appia, ReverbNation, Bronto, Brooks Bell - and many more.

Inc. 5000 Inc. 5000

Updated 7:39 a.m. Wednesday

Clinical trials tech firm Clinverse raises $9.1M, eyes 'more aggressive' strategy

Clinverse, which focuses on financial management tools to be used in clinical trials, has raised $9.1 million in a new round of venture capital funding. Durham-based Hatteras Venture Partners is part of the round.

Clinverse Clinverse

12:49 p.m. Tuesday

$4.1M federal grant could put BioCryst in Ebola fight - next time

It's tempting to think BioCryst might have the club that could beat down the frightening disease that's producing daily headlines out of West Africa. So far it's believed to have infected more than 2,100 people in 2014 and killed 1,145 in Guinea, Liberia, Nigeria and Sierra Leone. But this Ebola outbreak will most likely be history by the time BCX4430 becomes a useful clinical weapon.

Ebola virus Ebola virus

Updated 7:12 a.m. Tuesday

Former Intersouth VC Garheng Kong raises $110M fund

Garheng Kong, a former venture capitalist at Intersouth Partners in Durham who now lives in Silicon Valley, is the managing partner of a new venture fund that has raised $110 million.

Garheng Kong Garheng Kong

6:38 a.m. Tuesday

Biogen's newest MS drug to be manufactured in Triangle

Biogen's RTP plant The FDA on Friday approved the drug Plegridy from Biogen Idec as a treatment for multiple sclerosis. It will be manufactured in the Triangle.

6:38 a.m. Monday

Ebola puts focus on drugs made in tobacco plants

Ebola virus It's an eye-catching angle in the story of an experimental treatment for Ebola: The drug comes from tobacco plants. Medicago has a new production facility in Research Triangle Park. Once approved by federal authorities, it's expected to be able to make 30 million doses of seasonal flu vaccine a year, or 120 million vaccine doses to fight a major outbreak of "pandemic" flu if the government requests it.

Updated 6:21 a.m. Monday

Share your news with WRAL TechWire

Contribute to WRALTechWire WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.

6:19 a.m. Monday

Your 52 WRAL TechWire headlines from last week

Week in review Some local websites run one or two tech stories per day. Others a few more but mixed with a variety of business news. At WRAL TechWire, tech and life science make up the menu with more than 50 stories published over the last five business days. Here's a look back at technology, life science and other related news as reported in WRAL TechWire last week.

Updated August 15

Ebola outbreak brings global attention to tobacco plant-based drugs

It's an eye-catching angle in the story of an experimental treatment for Ebola: The drug comes from tobacco plants that were turned into living pharmaceutical factories. And one of the emerging players is Medicago, which operates a production facility in RTP.

How Medicago process works How Medicago process works

Updated August 14

Duke doctor warns against use of untested Ebola drugs

As more companies step up efforts to develop vaccines targeting ebola and the disease outbreak spreads in Africa, a doctor at Duke University warns that using untested drugs "could prove disastrous."

Liberia Ebola Liberia Ebola

Updated August 13

N.C. Biotechnology Center promotes exec to CEO post

The North Carolina Biotechnology Center has a new chief executive officer: Doug Edgeton, who already is a senior executive at the Center. He replaces Norris Tolson, who retired June 30.

Doug Edgeton Doug Edgeton

Updated August 13

RTP drug firm BioCryst receives $4.1M in federal funds for Ebola vaccine

Ebola fight  The National Institute of Allergy and Infectious Diseases has provided another $4.1 million in funding to Triangle-based BioCryst Pharmaceuticals for further development of a potential vaccine to treat Ebola.

August 13

Premium Lock Inside LipoScience: Study a 'significant event,' could drive health test sales

There's nothing like a major positive healthcare study to add credibility to a product. Just ask Howard Doran, chief executive officer at LipoScience. During a conference call to discuss the Raleigh-based firm's most recent earnings, Doran touted the study from the research arm of healthcare giant WellPoint as being an "important inflexion point" for adoption of the firm's cholesterol test.

A cholesterol ad included in LipoScience IPO filing A cholesterol ad included in LipoScience IPO filing

Techwire Inside Partners
The Skinny: A Blog by Rick Smith


Vivek Wadhwa
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science